Editing Stones: Diagnosis and Evaluation



'''See [[AUA: Evaluation and Medical Management of Stones (2019)|2019 AUA Evaluation and Medical Management of Stones]] Guideline Notes'''

==Imaging for Stone Disease==
===Plain Abdominal Film===
*'''Findings'''
**'''<span style="color:#ff0000">Radiolucent stones (6):</span>'''
***'''<span style="color:#ff0000">Uric acid</span>'''
***'''<span style="color:#ff0000">Matrix</span>'''
***'''<span style="color:#ff0000">Medication stones (4):</span>'''
****'''<span style="color:#ff0000">Xanthine</span>'''
****'''<span style="color:#ff0000">Triamterene</span>'''
****'''<span style="color:#ff0000">2,8-dihydroxyadenine</span>'''
****'''<span style="color:#ff0000">Indinavir</span>'''
**'''<span style="color:#ff0000">Radioopaque stones (4):</span>'''
***'''<span style="color:#ff0000">Calcium oxalate</span>'''
***'''<span style="color:#ff0000">Calcium phosphate</span>'''
***'''<span style="color:#ff0000">Poorly radioopaque:</span>'''
****'''<span style="color:#ff0000">Magnesium ammonium phosphate (struvite)</span>'''
****'''<span style="color:#ff0000">Cystine stones</span>'''
*****'''Although magnesium ammonium phosphate and cystine stones are often radioopaque, they are not as dense as calcium oxalate or calcium phosphate stones'''
**'''Nephrocalcinosis'''
***'''Formation of diffuse deposits of calcium throughout the kidneys'''
****'''Usually occurs within the renal medulla''' but occasionally it has been found in the cortex or within both the medulla and the cortex
****Minute calcifications seen in early stages may not be visible
***'''Can give rise to renal colic and hydronephrosis from dislodged calcific foci'''
***'''Causes[https://radiopaedia.org/articles/medullary-nephrocalcinosis §]'''
****'''Medulla'''
*****'''Type 1 (distal) RTA'''
*****'''Hyperparathyroidism'''
*****'''Medullary sponge kidney'''
*****'''Hypervitaminosis D'''
*****'''Milk-alkali syndrome'''
*****'''Sarcoidosis'''
*****'''Hyper/hypothyroidism'''
*****'''Other pathological hypercalcemic or hypercalciuric states'''
******'''Cushing syndrome'''
******'''Multiple myeloma'''
******'''Bartter syndrome'''
******'''Bone metastases'''
****'''Pyramids'''
*****'''Hyperuricemia'''
*****'''Infection (particularly renal tuberculosis)'''
*****'''Sickle cell disease (leading to infarction and subsequent dystrophic calcification)'''
*****'''Renal papillary necrosis'''
*****'''Drugs'''
*****'''Furosemide abuse'''
****'''Corticol COAG'''
*****'''Corticol necrosis'''
*****'''Oxalosis (Primary hyperoxaluria)'''
*****'''Alport syndrome'''
*****'''Glomerulonephritis (chronic)'''
***Insert Image  Plain film x-ray demonstrating bilateral diffuse calcium deposits in the kidneys  Source: Wikipedia
*Test characteristics[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
**Sensitivity: 57%
**Specificity: 76%
*Advantage(s)
**Availability
**Relatively low radiation exposure
***0.7 mSv with KUB[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
**Cost (least expensive)
*'''Disadvantages'''
**'''Inability to visualize small stones'''
**'''Inability to visualize stones due to overlying/underlying anatomy (bones, phleboliths, etc.)'''
**'''Underestimates >90% of stones >10mm'''
===Ultrasound===
*Test characteristics[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
**Sensitivity: 84%
**Specificity: 53%
*'''Advantages'''
**Availability
**No radiation exposure
**Cost (5x cost of KUB)[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
*'''Disadvantages (2):'''
**'''Inability to visualize most ureteral stones'''
**'''Poor correlation between measured and actual stone size and location'''
***'''If stone'''
****'''<10mm, US underestimates size of stone 1/3 of the time'''
****'''>10mm, US overestimates size of stone 1/3 of the time'''
***US and CT measurements correlate 2/3 of the time
===CT scan (without contrast)===
*'''Findings'''
**'''Pure uric acid stones have much lower Hounsfield units than calcium types'''
**'''Forniceal extravasation'''
***Usually associated with a small distal ureteral calculus.
***'''Should be similarly to other ureteral stones:''' intervention should be undertaken when there is an associated fever, nausea/vomiting, or unrelenting pain. Otherwise, conservative observation is appropriate.
*Test characteristics[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
**Sensitivity: 95%
**Specificity: 98%
*'''Advantages'''
**'''Most sensitive modality for stones'''
*Disadvantages
**Exposure to radiation[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
***Low-dose CT is ≈3.0 mSv, standard CT without contrast is 10.0 mSV
**Availability
**Cost (10x cost of KUB)[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
===MRI===
*Test characteristics[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
**Sensitivity: 82%
**Specificity: 98%
*Findings
**Stones appear as filling defects
*Advantages
**No exposure to radiation
*Disadvantages
**Availability
**Cost (most expensive, 30x cost of KUB)[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443345/ §]
==Acute Diagnosis and Management==
*'''Diagnosis and Evaluation'''
**'''History and Physical Exam'''
***History
****New-onset urgency and frequency may indicate a stone at the UVJ irritating the bladder
****Sudden relief of flank pain may indicate either passage or forniceal rupture as the pressure in the collecting system dramatically decreases.
***Physical Exam
****Abdomen
****Costovertebral angle tenderness
**'''Labs'''
***'''Urinalysis +/- culture'''
***'''CBC'''
***'''Serum creatinine'''
**'''Imaging'''
*'''Management'''
**Renal colic pain management[https://smhs.gwu.edu/urgentmatters/content/alternatives-opioids-pain-management-ed]
***Toradol 30 mg IV
***Cardiac Lidocaine 1.5 mg/kg IV in 100 mL NS over 10 minutes (MAX 200 mg)
***Acetaminophen 1000 mg PO
***1 L 0.9% NS bolus
**'''<span style="color:#ff0000">If obstructing stones with suspected infection, must urgently drain the collecting system with a stent or nephrostomy tube and delay stone treatment</span>[https://pubmed.ncbi.nlm.nih.gov/27238616/ ★]'''
***Definitive management of the stone should not be undertaken until sepsis has resolved and the infection has been treated with an appropriate course of antibiotic therapy.
==Diagnosis and Evaluation of Metabolic Stone Disease==
===UrologySchool.com Summary===
====AUA'''<span style="color:#ff0000">[https://pubmed.ncbi.nlm.nih.gov/24857648/ ★]</span>'''====
*'''<span style="color:#ff0000">Screening Evaluation</span>'''
**'''<span style="color:#ff0000">History and Physical Exam</span>'''
**'''<span style="color:#ff0000">Laboratory (5)</span>'''
**#'''<span style="color:#ff0000">Urinalysis +/- culture</span>'''
**#'''<span style="color:#ff0000">Serum electrolytes (Na, K, Cl, HCO3)</span>'''
**#'''<span style="color:#ff0000">Serum calcium</span>'''
**#'''<span style="color:#ff0000">Serum creatinine</span>'''
**#'''<span style="color:#ff0000">Serum uric acid</span>'''
**'''<span style="color:#ff0000">Imaging</span>'''
***'''<span style="color:#ff0000">Obtain or review available imaging studies to quantify stone burden.</span>'''
*'''<span style="color:#ff0000">Extended evaluation</span>'''
**'''<span style="color:#ff0000">One or two 24-hour urine collections</span>'''
***'''<span style="color:#ff0000">Indications (7):</span>'''
***#'''<span style="color:#ff0000">Recurrent stone formers</span>'''
***#'''<span style="color:#ff0000">Family history of stone disease</span>'''
***#'''<span style="color:#ff0000">Solitary kidney</span>'''
***#'''<span style="color:#ff0000">Malabsorptive intestinal disease or resection</span>'''
***#'''<span style="color:#ff0000">Obesity</span>'''
***#'''<span style="color:#ff0000">Recurrent UTIs</span>'''
***#'''<span style="color:#ff0000">Medical conditions predisposing to stones (e.g., RTA Type 1, primary hyperparathyroidism, gout, diabetes mellitus type)</span>'''
===Goals of Evaluation===
*'''Identify potential associated metabolic disorders such as (5)'''
*#'''Distal renal tubular acidosis (RTA)'''
*#'''Primary hyperparathyroidism'''
*#'''Enteric hyperoxaluria'''
*#'''Cystinuria'''
*#'''Gouty diathesis'''
*'''Reduce risk of stone recurrence'''
**First-time stone formers have been estimated to have a 50% risk for recurrence within the subsequent 10 years
**Patients at higher risk for repeat episodes (6):
**#Family history of stones
**#Intestinal disease (particularly when causing chronic diarrheal states)
**#Pathologic skeletal fractures
**#Osteoporosis
**#UTI
**#Gout
===History and Physical Exam===
====History====
*'''Screen for factors that predispose to calculi'''
**'''<span style="color:#ff0000">Conditions associated with stone disease (8):</span>'''
**#'''<span style="color:#ff0000">Obesity</span>'''
**#'''<span style="color:#ff0000">Hyperthyroidism</span>'''
**#'''<span style="color:#ff0000">Gout</span>'''
**#'''<span style="color:#ff0000">Renal tubular acidosis (RTA) type 1</span>'''
**#'''<span style="color:#ff0000">Diabetes mellitus type 2</span>'''
**#'''<span style="color:#ff0000">Bone disease</span>'''
**#'''<span style="color:#ff0000">Primary hyperparathyroidism</span>'''
**#'''<span style="color:#ff0000">Malabsorptive gastrointestinal states</span>''' due to bowel resection, bariatric surgery or bowel or pancreatic disease
**##Chronic diarrhea that could be caused by inflammatory bowel disease (Crohn disease, ulcerative colitis) or irritable bowel syndrome
**##Gout may predispose the patient to hyperuricosuria or gouty diathesis with either uric acid calculi or calcium oxalate stone formers
**##Surgical history should be obtained focusing particularly on bariatric surgery and surgeries of the intestinal tract.
**###Roux-en-Y-gastric bypass surgery may significantly increase the overall risk for stone formation
**###'''In contrast to gastric bypass surgery, restrictive bariatric surgeries such as gastric sleeve or gastric band do not seem to increase the risk for kidney stones'''
**'''<span style="color:#ff0000">Dietary history</span>'''
***'''Should include average daily intake of fluids (amount and specific beverages), protein (types and amounts), calcium, sodium, high oxalate-containing foods, fruits and vegetables and over-the-counter supplements.'''
****'''Nutritional factors associated with stone disease, depending on stone type and risk factors, include'''
*****Calcium intake below or significantly above the recommended dietary allowance (RDA)
*****Low fluid intake
*****High sodium intake
*****Limited intake of fruits and vegetables
*****High intake of animal-derived purines
**'''<span style="color:#ff0000">Medications</span>'''
***'''Stone-provoking medications or supplements (9):'''
***#'''Probenecid'''
***#'''Some protease inhibitors'''
***#'''Lipase inhibitors'''
***#'''Triamterene'''
***#'''Chemotherapy'''
***#'''Vitamin C'''
***#'''Vitamin D'''
***#'''Calcium'''
***#'''Carbonic anhydrase inhibitors such as topiramate, acetazolamide, zonisamide'''
====Physical Exam====
*'''Body mass index'''
**'''Increased BMI, larger waist size, and weight gain are correlated with an increased risk for stone episodes'''
***'''The association of obesity and uric acid stone formation is primarily due to change in urinary pH'''
***'''The association of obesity with calcium oxalate stone formation is primarily due to increased excretion of promoters of stone formation''' (oxalate, uric acid, sodium, and phosphorus)
===Laboratory===
====<span style="color:#ff0000">Urinalysis +/- culture +/- microscopy</span>====
*'''<span style="color:#ff0000">Urinalysis should include pH</span>'''
**'''<span style="color:#ff0000">pH > 7.0 is suggestive of infection lithiasis or RTA</span>'''
**'''<span style="color:#ff0000">pH < 5.5 suggests uric acid lithiasis secondary to gouty diathesis</span>'''
*'''Urine culture'''
**'''Should be obtained in patients with a urinalysis suggestive of UTI.'''
**'''Presence of urea-splitting organisms, such as Proteus species, raises the possibility of struvite stones'''
**Many infected calculi will harbor bacteria even after treatment with broad-spectrum antibiotics
**Half of infected calculi grow bacterial cultures that are different from the preoperative urine specimen
*'''Urine microscopy'''
**'''Identify crystals pathognomonic of stone type.'''
====<span style="color:#ff0000">Serum chemistries</span>====
*'''<span style="color:#ff0000">Includes</span>'''
*#'''<span style="color:#ff0000">Electrolytes (Na, K, Cl, HCO3)</span>'''
*#'''<span style="color:#ff0000">Calcium</span>'''
*#'''<span style="color:#ff0000">Uric acid</span>'''
*#'''<span style="color:#ff0000">Creatinine</span>'''
*May suggest underlying medical conditions associated with stone disease (e.g., primary hyperparathyroidism, gout, RTA type 1 or other metabolic derangements)
*'''Assessment of underlying renal function is necessary'''
====<span style="color:#ff0000">Parathyroid hormone (PTH)</span>====
*'''<span style="color:#ff0000">Indicated as part of the screening evaluation if primary hyperparathyroidism is suspected</span>'''
**'''<span style="color:#ff0000">Primary hyperparathyroidism should be suspected when (3):</span>'''
**#Mid-range PTH despite '''<span style="color:#ff0000">high or high normal serum calcium</span>'''
**#'''<span style="color:#ff0000">Increased urinary calcium</span>'''
**#'''<span style="color:#ff0000">Predominantly calcium phosphate stone composition</span>'''
*'''Measurement of vitamin D levels may be helpful as''' '''low vitamin D levels may mask primary hyperparathyroidism, or contribute to secondary hyperparathyroidism.'''
*A high or high normal intact PTH in these settings should prompt further endocrine evaluation, imaging or referral for consideration of parathyroidectomy.
====Stone composition, if available====
*'''When a stone is available, a stone analysis should be obtained at least once.'''
*Can direct metabolic investigation or potentially obviate the need for a complete metabolic evaluation
*'''<span style="color:#ff0000">Calcium phosphate stone composition associated with:</span>'''
*#'''<span style="color:#ff0000">RTA Type 1</span>'''
*#'''<span style="color:#ff0000">Primary hyperparathyroidism</span>'''
*#'''<span style="color:#ff0000">Medullary sponge kidney</span>'''
*#'''<span style="color:#ff0000">Use of carbonic anhydrase inhibitors</span>'''
===Imaging===
*'''Obtain or review available imaging studies to quantify stone burden.''' '''<span style="color:#ff0000">[https://pubmed.ncbi.nlm.nih.gov/24857648/ ★]</span>'''
===Metabolic/Extended Diagnostic Evaluation===
*'''<span style="color:#ff0000">Consists of one or two 24-hour urine collections obtained on a random diet[https://pubmed.ncbi.nlm.nih.gov/24857648/ ★]</span>'''
====Indications====
*'''<span style="color:#ff0000">AUA (7):[https://pubmed.ncbi.nlm.nih.gov/24857648/ ★]</span>'''
*#'''<span style="color:#ff0000">Recurrent stone formers</span>'''
*#'''<span style="color:#ff0000">Family history of stone disease</span>'''
*#'''<span style="color:#ff0000">Solitary kidney</span>'''
*#'''<span style="color:#ff0000">Malabsorptive intestinal disease or resection</span>'''
*#'''<span style="color:#ff0000">Obesity</span>'''
*#'''<span style="color:#ff0000">Recurrent UTIs</span>'''
*#'''<span style="color:#ff0000">Medical conditions predisposing to stones (e.g., RTA Type 1, primary hyperparathyroidism, gout, diabetes mellitus type)</span>'''
*Included in other lists
*#Pathological skeletal fractures
*#Osteoporosis
*#Infirm health (unable to tolerate repeat stone episodes)
*#Anatomic abnormalities
*#Stones composed of cystine, uric acid, and struvite
*#Children should generally be evaluated because of concerns about renal damage and long-term sequelae of stone recurrence
====<span style="color:#ff0000">24-hour urine collections</span>====
*Can be used to inform and monitor treatment protocols
*'''<span style="color:#ff0000">Analyzed at minimum for (9): [https://pubmed.ncbi.nlm.nih.gov/24857648/ ★]</span>'''
*#'''<span style="color:#ff0000">Volume</span>'''
*#'''<span style="color:#ff0000">pH</span>'''
*#'''<span style="color:#ff0000">Creatinine</span>'''
*#'''<span style="color:#ff0000">Sodium</span>'''
*#'''<span style="color:#ff0000">Potassium</span>'''
*#'''<span style="color:#ff0000">Calcium</span>'''
*#'''<span style="color:#ff0000">Oxalate</span>'''
*#'''<span style="color:#ff0000">Uric acid</span>'''
*#'''<span style="color:#ff0000">Citrate</span>'''
*#'''In stone formers with known cystine stones or a family history of cystinuria or for those in whom cystinuria is suspected, urinary cystine should additionally be measured.'''
*#Sulfate can be added to assess the volume of protein loading from animal meat

*The accuracy of a 24-hour urine collection should be assessed prior to interpretation of results.
**'''To assess the adequacy of collection, 24-hour urinary creatinine excretion, taking into account patient gender and body weight,''' as well as patient recall of the start and end times of his or her collection, '''should be considered'''
***'''Significant aberrations in total creatinine excretion from estimated volumes (males 20-25mg/kg and females 15-20mg/kg in 24 hours) imply incomplete collection, overcollection, greater than expected muscle mass, or less than expected muscle mass'''
****For abnormally collected 24 hour urine collections, can divide metabolite excretion by creatinine excretion to compare collections
*'''Markers of protein intake, such as urine urea nitrogen or urinary sulfate, are reflective of animal protein intake and can be used to assess dietary adherence'''.
*Urinary potassium measured at baseline can be compared to urinary potassium obtained during follow-up to gauge compliance with medication regimens.
*'''Primary hyperoxaluria should be suspected when urinary oxalate excretion > 75 mg/day in adults without bowel dysfunction. These patients should be considered for referral for genetic testing and/or specialized urine testing'''
*Fast and calcium load testing should not be performed routinely to distinguish among types of hypercalciuria
*If a patient with calcium urolithiasis uses calcium supplements, 24-hour urine samples should be collected on and off the supplement.
**If urinary supersaturation of the calcium salt in question increases during the period of supplement use, the supplement should be discontinued.
==Questions==
#What is the risk of stone recurrence at 10 years in first-time stone formers?
#What is the microscopic appearance of common urinary calculi?
==Answers==
1. 50%
==Next Chapter: [[Stones: Surgical Modalities for Management of Upper Urinary Tract Calculi|Surgical Modalities for Management of Upper Urinary Tract Calculi]]==
==References==
*Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, chap 52
*[https://pubmed.ncbi.nlm.nih.gov/24857648/ Pearle, Margaret S., et al. "Medical management of kidney stones: AUA guideline." ''The Journal of urology'' 192.2 (2014): 316-324.]